Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH), consisting of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid moiety conjugated to the N-terminus. CAS 218949-48-9, molecular weight approximately 5135.77 g/mol. The trans-3-hexenoic acid modification confers greater resistance to dipeptidyl peptidase IV (DPP-IV) enzymatic cleavage compared to native GHRH.Tesamorelin has been studied extensively in the context of pituitary somatotroph biology and GH axis regulation. Research applications include investigations of GHRH receptor signaling mechanisms, hypothalamic-pituitary axis modeling, and the comparative pharmacology of full-length versus truncated GHRH analogs. Its stability profile makes it a useful research tool for studying sustained GHRH receptor engagement in cell culture systems. Note: Tesamorelin (Egrifta) is FDA-approved for a specific clinical indication; this compound is supplied strictly for non-clinical laboratory research.
Supplied as a lyophilized powder. Each lot is independently tested by HPLC-UV with a minimum purity threshold of ≥99.0%. Molecular identity confirmed by LC-MS prior to release. Certificate of Analysis available for every lot number.
For laboratory and in-vitro research use only. Not for human or veterinary use. Not FDA approved.